Mirabegron - a new drug for treatment of overactive bladder


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Mirabegron is the first drug in a new class of oral therapy for overactive bladder (OAB). It is a beta-3 adrenergic agonist, a class of drugs for the first time used for the treatment of urination disorders. Recently, following many years of rigorous multicenter randomized trials mirabegron has been approved for use in Europe and North America. The clinical indication for mirabegron is overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency and other storage symptoms in both men and women.
Mirabegron is used in primary patients, or in patients who previously were unsuccessfully treated with anticholinergics. The drug has a good safety profile and causes no side effects typical of anticholinergics.

About the authors

G R Kasjan

A.I. Evdokimov Moscow State University of Medicine and Dentistry

A.I. Evdokimov Moscow State University of Medicine and Dentistry

References

  1. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., Wein A.; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol. Urodyn. 2002;21:167-178.
  2. Milsom I., Abrams P., Cardozo L., Roberts R., Thuroff J., Wein A. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760-766.
  3. D'Souza A., Smith M., Miller L., Doyle J., Ariely, R. Persistence, adherence, and switch rates among extended-release and immediate- release overactive bladder medications in a regional managed care plan.
  4. J. Manag. Care Pharm. 2008;14:291-301.
  5. Takeda M., Obara K., Mizusawa T., Tomita Y., Arai K., Tsutsui T., Hatano A., Takahashi K., Nomura S. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther. 1999;288:1367-1373.
  6. Sacco E., Tienforti D., DAddessi A., Pinto F., Racioppi M., Totaro A., D'Agostino D., Marangi F., Bassi P. Social, economic, and health utility considerations in the treatment of overactive bladder. J. Urol. 2010;2:11-24.
  7. Takasu T., Ukai M., Sato S. Matsui T., Nagase I., Maruyama T., Sasamata M., Miyata K., Uchida H., Yamaguchi O. Effect of (R)-2- (2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl) amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J. Pharmacol. Exp. Ther. 2007;321:642-647.
  8. Takeda H., Yamazaki Y., Akahane M., Igawa Y., Ajisawa Y., Nishizawa O. Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J. Pharmacol. Exp. Ther. 2000; 293:939-945.
  9. Chapple C., Kaplan S., Mitcheson H., Klecka J., Cummings J., Drogendijk T., Dorrepaal C., Martin N. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a |3(3)-adrenoceptor agonist, in overactive bladder. Eur. Urol. 2012;11:e683-e683a.
  10. Igawa Y., Aizawa N., Homma, Y. Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J. Urol. 2010;51:811-818.
  11. Kaidoh K., Igawa Y., Takeda H., Yamazaki Y., Akahane S., Miyata H., Ajisawa Y., Nishizawa O., Andersson K.E. Effects of selective |32 and p3-adrenoceptor agonists in detrusor hyperreflexia in conscious cerebral infarcted rats. J. Urol. 2002 ;168(3):1247-1252.
  12. Kanai A., Wyndaele J., Andersson K., Fry C., Ikeda Y., Zabbarova I., De Wachter S. Research in bladder afferents determining the effects of b3-adrenergic receptor agonists and botulinumtoxin type-A. Neurourol. Urodyn. 2011;30:684-691.
  13. Yamaguchi O., Chapple C. b3-Adrenoceptors in urinary bladder. Neurourol. Urodyn. 2007;26:752-756.
  14. Lindholm P., Lose G. Terbutaline (Bricanyl) in the treatment of female urge incontinence. Urol. Int. 1986;41:158-160.
  15. Gruneberger A. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. Br. J. Obstetr. Gynaecol. 1984;91: 275278. 15.
  16. FDA (2012) Summary of safety and efficacy as basis for Advisory Committee briefing document for mirabegron, <http://www.fda.gov/> downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ReproductiveHealthDrugsAdvisoryCommittee/UCM298284.pdf.
  17. Takusagawa S., vanLier J., Suzuki K., Nagata M., Meijer J., Krauwinkel W. Schaddelee M., Sekiguchi M., Miyashita A., Iwatsubo T., van Gelderen M., Usui T. Absorption, metabolism and excretion of [14C]mirabegron (YM178), a potent and selective p3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug. Metab. Dispos. 2012;40:815-824. 17.
  18. van Gelderen E., Li Q., Meijer J., Schaddelee M., Takusagawa S., Sugawarw T., et al. An explanatory comparison of the single dose pharmacokinetics of the beta3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin. Pharmacol. Ther. 2009;85(1):PIII-65
  19. Chapple C., Yamaguchi O., Ridder A., Liehne J., Carl S., Mattiasson A., et al. Clinical proof of concept study (Blossom) shows novel b3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur. Urol. Suppl. 2008;7:239 (abstract 674).
  20. Chapple C., Wyndaele J., VanKerrebroeck P., Radziszewski P., Dvorak V., Boerrigter, P. Dose-ranging study of once-daily mirabegron (YM178), a novel selective 3-adrenoceptoragonist, in patients with overactive bladder (OAB). Eur. Urol. 2010;9:249.
  21. Khullar V., Cambronero J., Angulo J., Wooning M., Blauwet M., Dorrepaal C., Martin N.E. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): post-hoc analysis of a prospective, randomised European- Australian phase III trial. BMC Urol. 2013;13:45.
  22. Nitti V., Herschorn S., Auerbach S., Ayers M., Lee M., Martin, N. The selective [beta] 3-adrenoreceptor agonist mirabegron is effective and well tolerated in patients with overactive bladder syndrome. J. Urol. 2011; 185: e783-e784.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies